Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call [Yahoo! Finance]
Zai Lab Limited - American Depositary Shares (ZLAB)
US:NASDAQ Investor Relations:
zailaboratory.com/about/investors.php
Company Research
Source: Yahoo! Finance
SCLC patients with brain metastases (62% at the 1.6 mg/kg dose) with 17% complete responses, rapid onset of effect and a median time on response of nine months, while safety was manageable (primarily myelosuppression and GI symptoms) with no new intracranial safety signals reported. In extrapulmonary neuroendocrine carcinomas and other DLL3-expressing tumors, zoci produced a 38% ORR and ~56% disease control rate (33% in GEP-NEC, 44% in other EP-NECs), with responses observed regardless of DLL3 IHC status but possible reduced activity after prior irinotecan/topoisomerase-1 exposure. Zai Lab is advancing zoci globally, with the Phase III DLLEVATE study ongoing (expected enrollment completion H1 2027 and potential accelerated approval in 2028), and multiple combination programs planned or underway with Amgen and Boehringer Ingelheim to evaluate PD-L1, T-cell engager, and chemotherapy triplet strategies in first-line and later settings. Interested in Zai Lab Limited Unsponsored ADR?
Show less
Read more
Impact Snapshot
Event Time:
ZLAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZLAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZLAB alerts
High impacting Zai Lab Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ZLAB
News
- Assessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target Reset [Yahoo! Finance]Yahoo! Finance
- Zai Lab (ZLAB) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (e+)" to "sell (d-)".MarketBeat
- Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026Business Wire
- Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases Transcript [Seeking Alpha]Seeking Alpha
- Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy [Yahoo! Finance]Yahoo! Finance
ZLAB
Earnings
- 2/26/26 - Miss
ZLAB
Sec Filings
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- 4/8/26 - Form 4
- ZLAB's page on the SEC website